RT Journal Article
SR Electronic
T1 <em>AnmO</em><sub>2</sub><em>l</em>: An open-source pulse-dose oxygen conserving device for the COVID-19 crisis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.19.21257477
DO 10.1101/2021.05.19.21257477
A1 Li, Honquan
A1 Krishnamurthy, Deepak
A1 Kothari, Anesta
A1 Li, Ethan
A1 Lipnick, Michael
A1 Gaba, David
A1 Fanning, Ruth
A1 Prakash, Manu
YR 2021
UL http://medrxiv.org/content/early/2021/05/21/2021.05.19.21257477.abstract
AB The surge of COVID-19 cases in India and around the world has resulted in acute oxygen shortage. Oxygen therapy through nasal cannula with flow rates of 1-6 L/min is an effective treatment for many COVID-19 patients in non-critical conditions and may help prevent disease progression. The same treatment is also used in post-acute care for recovering COVID-19 patients. Here we describe a simple, open source, and rapidly manufacturable oxygen conservation device for use with dual-port nasal cannula that can extend the life of current oxygen supply by almost two to three times, which we hope will help towards coping with the ongoing crisis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No patient data collected. The device is in pre-clinical phase.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data available at www.anmo2l.org https://anmo2l.org/